Pedro Pita Barros is the BPI | Fundação “la Caixa” Professor of Health Economics at Nova School of Business and Economics, Universidade Nova de Lisboa. He holds a PhD in Economics and his research ...

Professor Cookson argues that value-based pricing would benefit patients and health systems while ensuring ongoing investment in pharmaceutical innovation is incentivised. Professor Graham Cookson, ...

Dr. Jacoline Bouvy is the Programme Director of Medicines Evaluation at the National Institute for Health and Care Excellence (NICE). She is responsible for the delivery of medicines guidance produced ...

Bhaven N. Sampat is an economist by training, a Professor at the Department of Health Policy and Management at Columbia University, and a Research Associate at the National Bureau of Economic Research ...

Should Health Technology Assessment Include the Bereavement Effect on Health-Related Quality of Life? What Difference Could It Make to Decisions About Life-Extending Treatments? Chris Skedgel ...

Koonal is an associate director in the Science Policy and Research team at the National Institute for Health and Care Excellence. His project portfolio includes overseeing the NICE Listens ...

Siva is chief analyst in the policy team, leading on projects covering NHS funding, finances, productivity and performance. Before joining the Fund in 2017, Siva was head of analysis at NHS Providers ...

George joined OHE in August 2023 as an economist. His previous experience involved working on trial-based economic evaluations at University College London (UCL), focusing on the areas of primary care ...

Phill has over 25 years’ experience in the use of pharmaceutical industry data and information. His research interests include the economics of the pharmaceutical market, the productivity, and outputs ...